Overview
Status
Active
Registry date
2016-03-24
Share capital
5,000.00 PLN
Registered address
ul. Jurija Gagarina 5/102, 87-100 Toruń, Poland
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $1 |
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 76 days late).
- 202526/06/2026
- 202429/05/2025
- 202318/06/2024
- 202211/07/2023
- 202129/09/2022
- 2020filed
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 8.55MedianUSD 55.24kAverageUSD 2.70m
Net profit
This companyUSD 0.26MedianUSD -1.27kAverageUSD -92.18k
Operating costs
This companyUSD 7.53MedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 3.32kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Arkadiusz Michał Jundziłł – Vice President of the Management Board
Marta Pokrywczyńska – President of the Management Board
Manner of representation
A declaration of will on behalf of the company is made by the President of the Management Board. In the case of a multi-member management board, each member of the management board is authorised to make declarations of will on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 24 | $324.15 | 24% | |
Tomasz Adam Drewaage 56 | 25 | $337.66 | 25% |
Arkadiusz Michał Jundziłłage 47 | 25 | $337.66 | 25% |
Marta Pokrywczyńskaage 43 | 26 | $351.16 | 26% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 18, 2017 | Aid for SMEs for innovation support | $26,468$26,468 | MARSZAŁEK KUJAWSKO-POMORSKI |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-12-01 | Provision of advisory services to increase the scope of commercialisation of R&D results at Stem Cell Therapies | $25,358$25,358 | Regional Operational Programme of the Kujawsko-Pomorskie Voivodeship for 2014–2020 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| InventionbioS.A. | $17,762,977.76 | inventionbio.pl | ||
| Immbionicsp. z o.o. | $31,756.23 | immbionic.com.pl | ||
| Passio Human Microbiomesp. z o.o. | $1,856.58 | passiohumanmicrobiome.com | ||
| Fungotechsp. z o.o. | $187.68 | fungo.tech | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com | ||
| Ncage TherapeuticsS.A. | $29.14 | ncage.org | ||
| Innervisionsp. z o.o. | $4.54 | innervision.pl | ||
| ImmunotronicsP.S.A. | $0.16 | immunotronics.net | ||
| Passio Biomaterialssp. z o.o. | $0.00 | passio.pl | ||
| SONO Livesp. z o.o. | – | sonolive.eu |
FAQ
The main business activity of Stem Cell Therapies focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on March 24, 2016.
The headquarters is located at: ul. Jurija Gagarina 5, 87-100 Toruń.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $9, representing an increase of 19.8% compared to 2023.
No, the company recorded a net loss of $193 in 2024. For comparison, in 2023 the loss was $493, meaning the company reduced its loss by 62.8%.
Last updated: 2026-07-11
